NCT07105488 - A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis | Biotech Hunter

Enrollment

225

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

March 31, 2027

Conditions

Atopic Dermatitis (AD)

Interventions

BIOLOGICAL

BFB759

BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including atopic dermatitis

DRUG

Placebo

Placebo for BFB759

Trial Locations (7)

11797

RECRUITING

Vitality Clinical Trials LLC, Woodbury

32789

RECRUITING

Conquest Research LLC, Winter Park

33162

RECRUITING

Ziaderm Research LLC, North Miami Beach

44124

RECRUITING

Apex Clinical Research Center, LLC, Mayfield Heights

70006

RECRUITING

Clinical Trials Management, LLC, Metairie

76092

RECRUITING

Stryde Research-Epiphany Dermatology, Southlake

93534

RECRUITING

Antelope Valley Clinical Trials, Lancaster